Related Experiment Video

Updated: Sep 14, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia

Fatemeh Ensafi Talemi1, Soudeh Ghafouri-Fard2

  • 1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Leukemia Research Reports
|July 21, 2025
PubMed

Insights

Non-coding RNAs influence treatment response in chronic myelogenous leukemia (CML). Understanding these molecules offers new strategies to overcome imatinib resistance in CML patients.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Imatinib is a first-line therapy for chronic myelogenous leukemia (CML).
  • A subset of CML patients develop resistance to imatinib.
  • Non-coding RNAs (ncRNAs) are increasingly recognized as regulators of drug response.

Purpose of the Study:

  • To review the role of non-coding RNAs in modulating imatinib resistance in CML.
  • To identify novel ncRNA candidates for therapeutic intervention.

Main Methods:

  • Literature review of studies investigating ncRNAs and imatinib resistance in CML.
  • Analysis of molecular mechanisms by which ncRNAs affect tyrosine kinase inhibitor response.

Main Results:

  • Various classes of non-coding RNAs have been shown to impact imatinib efficacy.
  • These ncRNAs can either promote or overcome imatinib resistance.
  • Understanding ncRNA function provides insights into CML treatment failure.

Conclusions:

  • Non-coding RNAs play a significant role in the molecular landscape of imatinib resistance in CML.
  • Targeting specific ncRNAs presents a promising avenue for developing novel therapeutic strategies.
  • Further research into ncRNA biomarkers and therapeutics is warranted to enhance CML treatment outcomes.
Keywords:
Chronic myelogenous leukemiaImatinibcircRNAlncRNAmiRNA

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K